JF
NMRA icon

Jump Financial’s Neumora Therapeutics NMRA Stock Holding History

Jump Financial’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,691
Closed -$11.5K – 2062
2025
Q2 		$11.5K Sell
15,691
-9,256
-37% -$7.01K ﹤0.01% 1734
2025
Q1 		$24.9K Buy
+24,947
New +$42.7K ﹤0.01% 1532

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Jump Financial's NMRA Position: Q3 2025 in Review

Jump Financial sold out of Neumora Therapeutics (NMRA) in Q3 2025, closing a stake of 15,691 shares — an estimated $11.5K sold.

Jump Financial first reported a position in NMRA in Q1 2025 and held it in 2 quarters. The position peaked at $24.9K in Q1 2025. 93 funds tracked by Wall St. Rank hold NMRA as of Q3 2025.

  • Jump Financial reported no remaining Neumora Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Jump Financial sold 15,691 Neumora Therapeutics shares in Q3 2025, an estimated $11.5K.
  • Jump Financial first reported a position in Neumora Therapeutics in Q1 2025 and held it in 2 quarters.
  • Jump Financial's Neumora Therapeutics position peaked at $24.9K in Q1 2025.
  • 93 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q3 2025.

Based on Jump Financial's 13F filing for Q3 2025, filed 13 Nov 2025.